World’s First Solid-Tumor CAR-T Therapy Begins Rollout in China With First Foreign PatientYicai·Aug 19 at 06:38 AM02171-2.37%
CARsgen Therapeutics Announces 2026 Interim ResultsPR Newswire·Aug 18 at 07:15 PM02171-2.37%000963-3.38%
CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionPUBT·Aug 18 at 09:28 AM02171-2.37%000963-3.38%
CARsgen says NMPA clears IND for CT1190B in relapsed/refractory large B-cell lymphomaPUBT·Aug 6 at 07:00 PM02171-2.37%
CARsgen Therapeutics schedules board meeting to review interim resultsPUBT·Aug 6 at 04:31 AM02171-2.37%
CARsgen says CT0596 wins NMPA IND clearance for relapsed/refractory multiple myelomaPUBT·Aug 3 at 07:01 PM02171-2.37%
‘Systemic leap’: China’s drug innovation push yields bumper cropSCMP·Jul 20 at 06:03 PM02171-2.37%688192+0.29%
CARsgen files HKEX next-day disclosure return, issues 2,000 new shares via option exercisePUBT·Jul 17 at 09:36 AM02171-2.37%
CARsgen says satri-cel gastric cancer consolidation trial shows no recurrences to datePUBT·Jul 14 at 07:00 PM02171-2.37%
CARsgen Launches Discretionary Share Buyback Worth Up to 5% of CapitalTip Ranks·Jun 25 at 11:38 PM02171-2.37%
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitorbiopharmadive·Jun 24 at 09:32 AMMKKGY+0.59%SNY+1.55%
China’s CARsgen Slides for Second Day on Hefty Price Tag for World’s First Solid Tumor CAR-T TherapyYicai·Jun 24 at 07:03 AM02171-2.37%
CARsgen Wins First-Ever Global Approval for Solid-Tumor CAR T Therapy in ChinaTip Ranks·Jun 22 at 03:42 AM02171-2.37%
20:15 ETCARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026prnewswire·Jun 14 at 07:15 PM02171-2.37%
